INC makes key Japanese appoitnments
This article was originally published in Scrip
Clinical research organization INC Research has made three key management appointments in Japan. Hiromi Wakita has been named general manager and clinical director, leading the firm's operations in Japan. He joins INC from previous positions in both pharmaceutical companies and other CRO firms. Hiroshi Uoji has also joined the company as regulatory and safety director for Japan. Finally INC has named Shinichi Sato project director, CNS clinical development in Japan. All three new appointees will be based in the firm's Tokyo Office.
You may also be interested in...
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.